| 2019/06/28 17:14:03 | |
|---|---|
| Price | |
| 1.355 EUR | |
| Difference | -1.45% (-0.02) |
General attributes
| ISIN | CH0029850754 |
| Symbol | ADXN |
| Exchange | Frankfurt |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 5 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 1.355 EUR |
| High | 1.39 EUR |
| Low | 1.355 EUR |
| Close (prev. day) | 1.375 EUR |
| VWAP | 1.46 EUR |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 7 |
| Last size | 0 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: ADDEX THERAPEUTICS LIMITED |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/08/12 |
|
Global Equity Ratings |
|
| 2024/07/24 |
|
Global Equity Ratings |
|
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2019/06/28 17:14:03 | |
|---|---|
| Price | |
| 1.355 EUR | |
| Difference | -1.45% (-0.02) |
General attributes
| ISIN | CH0029850754 |
| Symbol | ADXN |
| Exchange | Frankfurt |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 5 EUR |
| Benchmark | SWISS MARKET INDEX |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 1.355 EUR |
| High | 1.39 EUR |
| Low | 1.355 EUR |
| Close (prev. day) | 1.375 EUR |
| VWAP | 1.46 EUR |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 7 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -30.33% | -43.31% | -45.19% |
| Perf (abs.) | -0.59 | -1.04 | -1.12 |
| Beta | 0.65 | 1.27 | 0.85 |
| Volatility | 42.51 | 37.67 | 43.45 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 1.409 EUR (0) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 1.419 EUR (33) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 1.526 EUR (98) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 1.877 EUR (134) |
| YTD High | date | 2.150 EUR (2019/01/08) |
| YTD Low | date | 1.330 EUR (2019/06/05) |
| 52 Weeks High | date | 2.470 EUR (2018/09/04) |
| 52 Weeks Low | date | 1.330 EUR (2019/06/05) |
All listings for ADDEX THERAPEUTICS LIMITED
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Stuttgart | 2019/06/28 | 15:43 | 1.37 EUR | 0.00 | 7 |
| SIX Swiss Exchange | 2024/08/16 | 17:31 | 0.052 CHF | 0.03 | 49 |
| London Stock Exchange | 2024/05/02 | 17:55 | 0.064 CHF | 0.01 | 1 |
| Frankfurt | 2019/06/28 | 17:14 | 1.355 EUR | 0.00 | 7 |
| Berlin | 2019/06/28 | 15:58 | 1.37 EUR | 0.00 | 5 |
Company Logo
Contact Details
| ADDEX THERAPEUTICS LTD. |
| - - |
| 9, Chemin des Mines, Plan-les-Ouates - 1202 Genf |
| Telefon: +41-22-884-15-55 |
| Fax: +41-22-884-15-56 |
| E-mail: info@addextherapeutics.com |
PDF Downloads
| Company report: ADDEX THERAPEUTICS LIMITED | |
Company Profile
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland. |
Members of Management Board
| Timothy Dyer | Chairman of Managing Board |
| Lénaic Teyssédou | Member of Executive Committee |
| Mikhail Kalinichev | Member of Executive Committee |
| Roger Mills | Member of Executive Committee |
Board of directors
| Isaac Manke | Member of the administrative board |
| Raymond Hill | Member of the administrative board |
| Roger Mills | Member of the administrative board |
| Jake Nunn | Member of the administrative board |
| Vincent Lawton | Chairman of the administrative boar |